Showing results (131-140 of 631) with videos related to
Sort By:
Pageof 64
European Journal of Biochemistry|May 1, 1997
Role of the carboxy-terminal domain of human apolipoprotein AI in high-density-lipoprotein metabolism--a study based on deletion and substitution variants in transgenic miceP Holvoet, S Danloy, D CollenEuropean Journal of Biochemistry|June 1, 1978
On the kinetics of the reaction between human antiplasmin and a low-molecular-weight form of plasminB Wiman, L Boman, D CollenThe American Journal of Cardiology|September 1, 1987
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarctionD Collen, F Van de WerfCirculation|June 1, 1993
Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarctionD Collen, F Van de WerfJournal of Thrombosis and Haemostasis : JTH|August 31, 2004
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in miceY Suzuki, N Nagai, D CollenBlood|January 1, 1987
Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibodyP Holvoet, J Boes, D CollenThrombosis and Haemostasis|October 30, 1985
Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PAP Holvoet, H Cleemput, D CollenCirculation|December 22, 1999
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster modelsN Nagai, I Vanlinthout, D CollenCirculation|June 15, 1999
Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistanceY Zhu, P Carmeliet, W P FayThe Journal of Biological Chemistry|September 20, 1997
Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cellsJ M Herbert, I Lamarche, P CarmelietPageof 64